![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
Phase I study of AMG-330: a BiTe for R/R AML patients (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
Updates from AMG 330 in AML (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
Update in T-cell recruiting antibody constructs for the treatment of AML (AML Hub) View |
![]() |
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma (ecancer) View |
![]() |
CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML (ecancer) View |
![]() |
Current immune checkpoint inhibitor trials in AML/MDS (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
Expert Discussions on Antibody-Based Therapy in AML (PeerView Oncology) View |
![]() |
First-in-human CLL1-CD33 compound CAR T-cells for AML (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
Dr. Michael Chu on CC-93269, a bispecific T-cell engager (BiTE) targeting BCMA and CD3, shows... (NE Live) View |
![]() |
ASH2014: Farhad Ravandi/ Vosaroxin VALOR (Oncoletter) View |